Skip to main content
. 2014 Nov 25;3:62. doi: 10.1186/s40169-014-0041-2

Figure 2.

Figure 2

C57BL/6 mice bearing GL261 glioma received 2 mg/kg/dose (approximately 40 μg/mouse) anti-mouse CCL2 mAb or control IgG twice weekly by i.p. injections starting on day 7 after tumor cell inoculation (n = 5/group). On day 24, mice were euthanized and isolated BILs were pooled from all mice in the same treatment group, and evaluated by flow cytometry for surface expression of CD11b and CD45 (A). Absolute numbers of CD11b + CD45 + (p = 0.0008) (B). Reproduced with permission [53].